Construction of a National Diagnosis and Treatment Quality Control Platform for Major Respiratory Diseases

January 13, 2023 updated by: Zhenguo Zhai,MD,PhD, China-Japan Friendship Hospital

Construction of a National Diagnosis and Treatment Quality Control Platform for Major Respiratory Diseases and Technical Promotion of Standardized Diagnosis and Treatment Programs

  1. Build a national diagnosis and treatment quality control platform for major respiratory diseases It will establish and improved a "National diagnosis and Treatment quality control Platform for major respiratory diseases", and form a three-level network of diagnosis and treatment quality control for major respiratory diseases with a three-level system structure of "national, provincial and hospital".
  2. Promote standardized diagnosis and treatment techniques for major respiratory diseases Relying on the specialized disease collaboration group or innovative unit model, all-round and hierarchical precision training and teaching are carried out to popularize and promote standardized diagnosis and treatment technology schemes for major respiratory diseases, so as to achieve the homogenization of diagnosis and treatment level for major respiratory diseases.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

  1. Build a national diagnosis and treatment quality control platform for major respiratory diseases Cooperate with the Medical Administration Administration of the National Health Commission, the Medical Administration Institute of the National Health Commission and the National Center for Respiratory Disease Medical Quality Control to integrate the existing diagnosis and treatment quality indicators and data from NCIS (National Medical Quality Management and Control Information Network) and HQMS (Hospital Quality Monitoring System), and determine the definition, data sources and collection rules of core quality control indicators. It has established and improved a "National diagnosis and Treatment quality control Platform for major respiratory diseases", and formed a three-level network of diagnosis and treatment quality control for major respiratory diseases with a three-level system structure of "national, provincial and hospital".
  2. To master the incidence trend and diagnosis and treatment quality of major respiratory diseases Through the big data integration and analysis function of the "National Diagnosis and Treatment Quality Control Platform for Major Respiratory Diseases", the incidence trend and law of various major respiratory diseases are mastered. To understand the difference in the diagnosis and treatment quality of respiratory diseases in hospitals of different regions and levels, including the allocation of related resources (such as personnel, technology, equipment, information construction, etc.); The status of diagnosis and treatment ability (prevention, diagnosis, treatment, rehabilitation, etc.); Current burden of disease (e.g. morbidity, case fatality rate, average length of stay, average cost of stay, etc.)
  3. Promote standardized diagnosis and treatment techniques for major respiratory diseases Relying on the specialized disease collaboration group or innovative unit model, through online and offline academic conferences, continuing medical education, specialized training, visits and exchanges, case discussions, knowledge competitions, wechat public accounts and other new media means, regularly focus on "prevention, diagnosis, treatment, rehabilitation, management, quality control" and many other aspects. Comprehensive and hierarchical precision training and teaching should be carried out to popularize and promote standardized diagnosis and treatment technology schemes for major respiratory diseases, so as to achieve the homogenization of diagnosis and treatment levels for major respiratory diseases.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Anticipated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
10000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China, 100029
        • China-Japanese Friendship Hosptial

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

People at high risk of VTE, people diagnosed with VTE

Description

Inclusion Criteria:

I. For patients at high risk for VTE 1) Have an expected hospital stay of ≥72 hours for medical and/or surgical treatment II. For patients diagnosed with VTE

1) With clearly diagnosed of deep vein thrombosis or pulmonary thromboembolism

Exclusion Criteria:

I. For patients at high risk for VTE

  1. VTE identified on CTPA or lower extremity vein ultrasound at or any time before enrollment
  2. Requiring a full dose of anticoagulant treatment before enrollment (e.g., recent VTE, atrial fibrillation).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Other

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
People at high risk for VTE
Patients who are admitted to the hospital for acute medical illness or surgery operations.
Other: Build a national diagnosis and treatment quality control platform for major respiratory diseases
  1. Build a national diagnosis and treatment quality control platform for major respiratory diseases
  2. To master the incidence trend and diagnosis and treatment quality of major respiratory diseases
  3. Promotion of standardized diagnosis and treatment techniques for major respiratory diseases
People diagnosed with VTE
Patients who were clearly diagnosed with deep vein thrombosis or pulmonary thromboembolism.
Other: Build a national diagnosis and treatment quality control platform for major respiratory diseases
  1. Build a national diagnosis and treatment quality control platform for major respiratory diseases
  2. To master the incidence trend and diagnosis and treatment quality of major respiratory diseases
  3. Promotion of standardized diagnosis and treatment techniques for major respiratory diseases

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
A respiratory quality control network platform has been established
Time Frame: 2025.01
A complete national quality control network platform for the diagnosis and treatment of major respiratory diseases with multi-source data has been built
2025.01

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
China-Japan Friendship Hospital

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Zhai Zhenguo, Doctor, Department of Respiratory and Critical Care Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2022

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 31, 2022

Study Completion (Anticipated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 31, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 29, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 13, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 18, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 18, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 13, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 12100000400014014Y

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings